Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.

Pharmacogenetics and genomics - 1 Nov 2013

Almoguera Berta, Riveiro-Alvarez Rosa, Lopez-Castroman Jorge, Dorado Pedro, Vaquero-Lorenzo Concepción, Fernandez-Piqueras José, Llerena Adrián, Abad-Santos Francisco, Baca-García Enrique, Dal-Ré Rafael, Ayuso Carmen

Abstract excerpt

The variability in the antipsychotic response is, to some extent, genetically determined. Several studies have attempted to establish a role for genetic variation in genes coding pharmacokinetic and pharmacodynamic targets, but to date, no definite genetic predictive marker has been identified. We aimed to explore the putative role of 19 genetic variants and risperidone clinical improvement in 76 White...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Biomarkers, Pharmacological

Share to Cytochrome P-450 CYP2D6

Share to Psychiatric Status Rating Scales

Share to Risperidone

Share to Schizophrenia

Source

Identifiers

PMID: 24026091
DOI: 10.1097/FPC.0b013e3283659a94

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.PMID 24026091Read ↗

Pharmacogenetics of Clinical Response to RisperioneSemantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

Pharmacogenetics of second-generation antipsychotics.Semantic proximity Read ↗

Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.Semantic proximity Read ↗

Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.Semantic proximity Read ↗

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.Semantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Semantic proximity Read ↗

Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.Semantic proximity Read ↗

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.